Article Dans Une Revue International Journal of Antimicrobial Agents Année : 2024

Enterobacterales carrying chromosomal AmpC β-lactamases in Europe (EuESCPM): Epidemiology and antimicrobial resistance burden from a cohort of 27 hospitals, 2020–2022

1 Azienda Ospedalerio - Universitaria Città della Salute e della Scienza di Torino = University Hospital Città della Salute e della Scienza di Torino
2 Hospital Universitario Insular de Gran Canaria [Las Palmas de Gran Canaria, Spain]
3 Serviço de Patologia Clínica, Centro Hospitalar Universitário Lisboa Norte, and Faculdade de Medicina. Universidade de Lisboa
4 Centro Hospitalar Universitário Lisboa Central
5 Chercheur indépendant
6 ISCIII - Instituto de Salud Carlos III [Madrid]
7 Hospital Universitario Ramón y Cajal [Madrid]
8 Vall d'Hebron University Hospital [Barcelona]
9 CHU Toulouse - Centre Hospitalier Universitaire de Toulouse
10 CHU Limoges
11 IMVA-HB - Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes
12 Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre]
13 Centre hospitalier Saint-Joseph [Paris]
14 MICALIS - MICrobiologie de l'ALImentation au Service de la Santé
15 Amsterdam UMC - Amsterdam University Medical Centers
16 KUH - Copenhagen University Hospital [Denmark] = Københavns Universitetshospital [Danmark]
17 OFFIS - Carl Von Ossietzky Universität Oldenburg = Carl von Ossietzky University of Oldenburg
18 Universitätsklinikum Jena = Jena University Hospital [Jena, Germany]
19 Faculty of Medicine – Semmelweis University
20 UZH - Universität Zürich [Zürich] = University of Zurich
21 UNIPA - Università degli studi di Palermo - University of Palermo
22 UNISS - Università degli Studi di Sassari = University of Sassari
23 University of Zagreb
24 KBC Split - University Hospital Center Split =
25 University of Ioannina
26 UOC - University of Crete [Heraklion]
27 Bilkent University [Ankara]
28 Başkent University Hospital [Adana, Turkey]
29 UMFT - Victor Babeş University of Medicine and Pharmacy
30 INBI - National Institute for Infectious Diseases “Matei Bals” [Bucharest, Romania]
31 ICUB - Research Institute of the University of Bucharest
32 Operative Unit of Clinical Pathology, Carlo Urbani Hospital, Jesi, Ancona
33 Nicolaus Copernicus University [Toruń]
34 ULISBOA - Universidade de Lisboa = University of Lisbon = Université de Lisbonne [Lisboa]
Delphine Chainier
  • Fonction : Auteur
Olivier Barraud
  • Fonction : Auteur
Eirini Christaki
Tuğba Yanık Yalçın

Résumé

Introduction: The ESCPM group (Enterobacter species including Klebsiella aerogenes - formerly Enterobacter aerogenes, Serratia species, Citrobacter freundii complex, Providencia species and Morganella morganii) has not yet been incorporated into systematic surveillance programs. Methods: We conducted a multicentre retrospective observational study analysing all ESCPM strains isolated from blood cultures in 27 European hospitals over a 3-year period (2020-2022). Diagnostic approach, epidemiology, and antimicrobial susceptibility were investigated. Results: Our study comprised 6,774 ESCPM isolates. MALDI-TOF coupled to mass spectrometry was the predominant technique for bacterial identification. Susceptibility to new β-lactam/β-lactamase inhibitor combinations and confirmation of AmpC overproduction were routinely tested in 33.3% and 29.6% of the centres, respectively. The most prevalent species were E. cloacae complex (44.8%) and S. marcescens (22.7%). Overall, third-generation cephalosporins (3GC), combined third- and fourth-generation cephalosporins (3GC + 4GC) and carbapenems resistance phenotypes were observed in 15.7%, 4.6%, and 9.5% of the isolates, respectively. AmpC overproduction was the most prevalent resistance mechanism detected (15.8%). Among carbapenemase-producers, carbapenemase type was provided in 44.4% of the isolates, VIM- (22.9%) and OXA-48-enzyme (16%) being the most frequently detected. E. cloacae complex, K. aerogenes and Providencia species exhibited the most notable cumulative antimicrobial resistance profiles, with the former displaying 3GC, combined 3GC + 4GC and carbapenems resistance phenotypes in 15.2%, 7.4%, and 12.8% of the isolates, respectively. K. aerogenes showed the highest rate of both 3GC resistant phenotype (29.8%) and AmpC overproduction (32.1%), while Providencia species those of both carbapenems resistance phenotype (42.7%) and carbapenemase production (29.4%). ESCPM isolates exhibiting both 3GC and combined 3GC + 4GC resistance phenotypes displayed high susceptibility to ceftazidime/avibactam (98.2% and 95.7%, respectively) and colistin (90.3% and 90.7%, respectively). Colistin emerged as the most active drug against ESCPM species (except those intrinsically resistant) displaying both carbapenems resistance phenotype (85.8%) and carbapenemase production (97.8%). Conclusions: This study presented a current analysis of ESCPM species epidemiology in Europe, providing insights to inform current antibiotic treatments and guide strategies for antimicrobial stewardship and diagnostics.

Fichier principal
Vignette du fichier
enterobacterales.pdf (1.17 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte
Licence

Dates et versions

hal-04792909 , version 1 (20-11-2024)

Licence

Identifiants

Citer

Matteo Boattini, Gabriele Bianco, Laura Iglesias Llorente, Laura Alonso Acero, Daniel Nunes, et al.. Enterobacterales carrying chromosomal AmpC β-lactamases in Europe (EuESCPM): Epidemiology and antimicrobial resistance burden from a cohort of 27 hospitals, 2020–2022. International Journal of Antimicrobial Agents, 2024, 63 (5), pp.107115. ⟨10.1016/j.ijantimicag.2024.107115⟩. ⟨hal-04792909⟩
158 Consultations
187 Téléchargements

Altmetric

Partager

  • More